Apyx Medical Corporation Announces Launch of Renuvion® in China
Apyx Medical Corporation (NASDAQ:APYX) has announced the launch of its Renuvion® technology in China, marking a significant expansion into one of the world's largest healthcare markets. The company has entered into a distribution agreement with GlamMoon Medical Technology, a division of BeauCare Clinics Investment Co., Ltd. (BCC), following initial market clearance from China's National Medical Products Administration.
The partnership with BCC, which operates over 60 medical aesthetics hospitals and clinics across 15 Chinese cities, positions Renuvion for significant market penetration. Early clinical interest and completed procedures indicate strong market potential for Apyx's helium plasma technology, which is supported by more than 90 clinical documents.
Apyx Medical Corporation (NASDAQ:APYX) ha annunciato il lancio della sua tecnologia Renuvion® in Cina, segnando un'importante espansione in uno dei più grandi mercati sanitari al mondo. L'azienda ha stipulato un accordo di distribuzione con GlamMoon Medical Technology, una divisione di BeauCare Clinics Investment Co., Ltd. (BCC), dopo aver ottenuto l'autorizzazione iniziale dalla National Medical Products Administration cinese.
La collaborazione con BCC, che gestisce oltre 60 ospedali e cliniche di medicina estetica in 15 città cinesi, posiziona Renuvion per una significativa penetrazione nel mercato. L'interesse clinico precoce e le procedure già completate indicano un forte potenziale di mercato per la tecnologia a plasma di elio di Apyx, supportata da più di 90 documenti clinici.
Apyx Medical Corporation (NASDAQ:APYX) ha anunciado el lanzamiento de su tecnología Renuvion® en China, marcando una expansión significativa en uno de los mayores mercados de salud del mundo. La compañía ha firmado un acuerdo de distribución con GlamMoon Medical Technology, una división de BeauCare Clinics Investment Co., Ltd. (BCC), tras obtener la aprobación inicial del mercado por parte de la Administración Nacional de Productos Médicos de China.
La alianza con BCC, que opera más de 60 hospitales y clínicas de estética médica en 15 ciudades chinas, posiciona a Renuvion para una penetración importante en el mercado. El interés clínico temprano y los procedimientos realizados indican un fuerte potencial de mercado para la tecnología de plasma de helio de Apyx, respaldada por más de 90 documentos clínicos.
Apyx Medical Corporation (NASDAQ:APYX)는 중국에서 Renuvion® 기술을 출시했다고 발표하며 세계 최대 의료 시장 중 하나로의 중요한 확장을 이루었습니다. 회사는 중국 국가의료제품관리국의 초기 시장 승인 후, BeauCare Clinics Investment Co., Ltd.(BCC)의 한 부서인 GlamMoon Medical Technology와 유통 계약을 체결했습니다.
BCC는 중국 15개 도시에 걸쳐 60개 이상의 의료 미용 병원 및 클리닉을 운영하고 있으며, 이 파트너십은 Renuvion의 시장 진입에 큰 기회를 제공합니다. 초기 임상 관심과 완료된 시술들은 Apyx의 헬륨 플라즈마 기술이 90개 이상의 임상 문서로 뒷받침되어 강력한 시장 잠재력을 지니고 있음을 보여줍니다.
Apyx Medical Corporation (NASDAQ:APYX) a annoncé le lancement de sa technologie Renuvion® en Chine, marquant une expansion significative dans l'un des plus grands marchés de la santé au monde. La société a conclu un accord de distribution avec GlamMoon Medical Technology, une division de BeauCare Clinics Investment Co., Ltd. (BCC), après l'autorisation initiale du marché par l'Administration nationale des produits médicaux de Chine.
Le partenariat avec BCC, qui exploite plus de 60 hôpitaux et cliniques d'esthétique médicale dans 15 villes chinoises, positionne Renuvion pour une pénétration importante du marché. L'intérêt clinique précoce et les procédures réalisées indiquent un fort potentiel de marché pour la technologie plasma à l'hélium d'Apyx, soutenue par plus de 90 documents cliniques.
Apyx Medical Corporation (NASDAQ:APYX) hat die Einführung seiner Renuvion®-Technologie in China bekannt gegeben und damit eine bedeutende Expansion in einen der größten Gesundheitsmärkte der Welt vollzogen. Das Unternehmen hat eine Vertriebsvereinbarung mit GlamMoon Medical Technology, einer Sparte von BeauCare Clinics Investment Co., Ltd. (BCC), nach der ersten Marktzulassung durch die chinesische National Medical Products Administration abgeschlossen.
Die Partnerschaft mit BCC, die über 60 medizinische Ästhetik-Krankenhäuser und Kliniken in 15 chinesischen Städten betreibt, positioniert Renuvion für eine bedeutende Marktdurchdringung. Frühes klinisches Interesse und abgeschlossene Verfahren deuten auf ein starkes Marktpotenzial für die Heliumplasmatechnologie von Apyx hin, die durch mehr als 90 klinische Dokumente unterstützt wird.
- Entry into China's large and fast-growing healthcare market through regulatory clearance
- Partnership with BCC, which operates 60+ medical aesthetics facilities across 15 cities
- Strong early clinical interest and successful initial procedures
- Technology backed by 90+ clinical documents supporting effectiveness
- Potential regulatory risks for expanded approvals in China
- Exposure to supply chain disruptions and component shortages mentioned in forward-looking statements
- Subject to macroeconomic and geopolitical risks in Chinese market
Insights
Apyx's Renuvion launch in China opens significant revenue potential in world's second-largest medical aesthetics market with established distribution partner.
Apyx Medical's entry into China with its Renuvion technology represents a strategic milestone in the company's international expansion efforts. China stands as the world's second-largest medical aesthetics market, valued at approximately
The partnership with GlamMoon Medical Technology (BeauCare Clinics' distribution division) provides Apyx with an established distribution network across 15 cities with connections to over 60 medical aesthetics facilities. GlamMoon's group purchasing alliance extends to 400+ alliance members across 30+ cities, offering Apyx immediate access to a robust commercialization infrastructure without building their own sales force.
The initial market clearance from China's National Medical Products Administration (NMPA) is significant, though the release indicates plans for expanded regulatory approvals, suggesting current clearance may be limited to specific indications or configurations. The helium plasma technology differentiates Renuvion in the competitive Chinese aesthetics device market by offering controlled subdermal tissue contraction with minimal thermal spread - addressing the prevalent concern of skin laxity in the region.
Early physician adoption and completed procedures demonstrate market validation, though no specific sales figures were provided. The timing aligns with China's growing emphasis on developing its domestic medical aesthetics sector, providing Apyx with favorable market conditions for introducing innovative technology. Investors should monitor future communications for expanded regulatory approvals, specific sales metrics, and physician adoption rates to evaluate the trajectory of this market entry.
Strong clinical interest and early procedures completed
Entered into distribution agreement with GlamMoon,
a division of BeauCare Clinics Investment Co., Ltd. post-initial market clearance
CLEARWATER, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”) today announced the launch of Renuvion® in China as part of its international commercialization strategy. A targeted sales and marketing campaign for Renuvion is being conducted through a distribution agreement covering China with GlamMoon Medical Technology, the wholly owned equipment distribution division of BeauCare Clinics Investment Co., Ltd. ("BCC"), a leading platform company in China’s medical aesthetics industry, following receipt of initial market clearance from the National Medical Products Administration of China.
“The launch of Renuvion in China marks a significant milestone in our global expansion strategy,” said Charlie Goodwin, President and CEO of Apyx Medical Corporation. “We are proud to bring our innovative technology to one of the world’s largest and fastest-growing healthcare markets. The strong interest and initial sales we have seen underscore the unmet need Renuvion addresses, and we look forward to working with our partners to improve patient outcomes. These recent activities will help establish a commercial foundation which we will build upon through expanded regulatory approvals for Renuvion in China.”
“We are excited to partner with Apyx Medical to bring this groundbreaking medical technology to the Chinese market,” said Ariel Liu, CEO of GlamMoon Medical Technology. “There is a clear demand for advanced solutions that improve patient care, and the early response from physicians has been very positive. We believe Renuvion has strong potential to become a standard of care in its category across China.”
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and now the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com. To learn more about how Renuvion or AYON can address loose skin concerns, and find a provider near you, visit www.Renuvion.com or https://ayonbody.com/.
About BeauCare Clinics Investment Co., LTD. (BCC):
Founded in 2013, BCC is a leading platform company in China’s medical aesthetics industry with businesses spanning medical services, supply chain and digital innovation. In medical services, BCC invests, controls, and operates over 60 medical aesthetics hospitals and clinics across 15 cities nationwide. It is the largest doctor entrepreneurship platform and the medical aesthetics group with the most chain members in China. Leveraging customer reputation and brand influence, BCC has built its own supply chain business with rapidly expanding portfolio of aesthetics products and devices, and established a group purchasing alliance with more than 400 alliance members across 30+ cities in China at the end of Q1 2025.
Cautionary Statement on Forward-Looking Statements:
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance.
Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Jeremy Feffer, Managing Director LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
FAQ
What is the significance of Apyx Medical's Renuvion launch in China?
Who is Apyx Medical's distribution partner for Renuvion in China?
What clinical evidence supports Renuvion's effectiveness?
How does this expansion align with APYX's business strategy?
What are the main applications of Renuvion technology?
